Tue, Jul 29, 2014, 12:57 AM EDT - U.S. Markets open in 8 hrs 33 mins


% | $
Click the to save as a favorite.

Incyte Corporation Message Board

whc60805 4 posts  |  Last Activity: Mar 7, 2014 11:56 AM Member since: Feb 29, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Annoying Posts

    by rman707 Mar 7, 2014 11:55 AM
    whc60805 whc60805 Mar 7, 2014 11:56 AM Flag


    Sentiment: Strong Buy

  • whc60805 by whc60805 Mar 7, 2014 11:55 AM Flag

    The reality is the results are great. Some of this was expected and bake in. I believe a lot of the selling is the big boys are driving down the price to scare retail investors to sell as well as to try to trip stop gap's. Seems to happen whenever the hedge funds want to pick up more stock at a lower price. In this case, it would be to acquire more INCY prior to the FDA giving approval for Polycythemia Vera which of course will drive up revenues and profits.

    Sentiment: Strong Buy

  • whc60805 by whc60805 Mar 6, 2014 11:11 AM Flag

    The reality is this treatment will be used in conjuction with a lesser amount of retroviral's to increase efficacy and decrease side effects. Just need to see more studies

    Sentiment: Strong Buy

  • Reply to


    by solarmanmike Mar 5, 2014 7:43 PM
    whc60805 whc60805 Mar 6, 2014 10:06 AM Flag

    I read some of the medical commentary this morning. It suggests that the ability to modify the T cells to express the CCR5 gene will enable treatment of HIV with much less retroviral meds then are required today with hopefully better results. My guess is this will become a co therapy if additional studies hold up and not a standalone therapy.

    Sentiment: Strong Buy

47.14-0.16(-0.34%)Jul 28 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.